3 Pharma Stocks That Are COVID-19 Resistant

The race for a novel coronavirus vaccine has lit a fuse under biotech and pharmaceutical companies. 2020 will surely be remembered as the year of COVID-19 and an unprecedented boom for these industries. During good times, pharma stocks are attractive because of their steady cash flow, high-profit margins, research and development innovations, and exclusivity of drug patents. But during a global pandemic, they become even more attractive because they are now essential to our future. They are now the superheroes who will protect the world against COVID-19. This also makes them recession-proof.


Pfizer Inc. (NYSE: PFE) has been a longtime favorite among investors due to its dividend. Despite being kicked off Dow Jones as it was replaced by the biotech company Amgen, Inc. (NASDAQ: AMGN), it is still one of the best bets when it comes to the COVID-19 vaccine. Yet, latest news reports that COVID-19 vaccine candidates being developed by Moderna Inc (NASDAQ: MRNA) and BioNTech SE (NASDAQ: BNTX) and Pfizer itself will require stringent standards for refrigeration. This factor could hamper how they are distributed. Unsurprisingly, stocks tumbled. On the other hand, there are about half a dozen COVID-19 vaccine candidates in clinical trials in the U.S but not all of them are mRNA vaccines. The vaccine being developed by AstraZeneca plc (NYSE: AZN) and the University of Oxford is a recombinant viral vector vaccine whereas the Inovio Pharmaceutical Inc’s (NASDAQ: INO) candidate is DNA-based. Competitive positioning will be …

Full story available on Benzinga.com

More 3 Pharma Stocks That Are COVID-19 Resistant